{"id":"https://openalex.org/W3216726396","doi":"https://doi.org/10.1097/nrl.0000000000000376","title":"Randomized Controlled Trials for Neuromyelitis Optica Spectrum Disorder","display_name":"Randomized Controlled Trials for Neuromyelitis Optica Spectrum Disorder","publication_year":2021,"publication_date":"2021-11-30","ids":{"openalex":"https://openalex.org/W3216726396","doi":"https://doi.org/10.1097/nrl.0000000000000376","mag":"3216726396","pmid":"https://pubmed.ncbi.nlm.nih.gov/34855669"},"language":"en","primary_location":{"id":"doi:10.1097/nrl.0000000000000376","doi":"https://doi.org/10.1097/nrl.0000000000000376","is_oa":false,"landing_page_url":"https://doi.org/10.1097/nrl.0000000000000376","pdf_url":null,"source":{"id":"https://openalex.org/S135892068","display_name":"The Neurologist","issn_l":"1074-7931","issn":["1074-7931","2331-2637"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Neurologist","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5141259516","display_name":"Ana Maria Cabal-Herrera","orcid":"https://orcid.org/0000-0002-4879-4896","observed_orcids":["https://orcid.org/0000-0002-4879-4896"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ana M. Cabal-Herrera","raw_affiliation_strings":["Department of Neurology, Massachusetts General Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurology, Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5062928592","display_name":"Farrah Jasmine Mateen","orcid":"https://orcid.org/0000-0002-4293-8115","observed_orcids":["https://orcid.org/0000-0002-4293-8115"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Farrah J. Mateen","raw_affiliation_strings":["Department of Neurology, Massachusetts General Hospital, Boston, MA","Farrah J. Mateen, MD, PhD, Department of Neurology, Massachusetts General Hospital, 165 Cambridge Street, Office 627, Boston, MA 02114. E-mail: [email\u00a0protected]"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurology, Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]},{"raw_affiliation_string":"Farrah J. Mateen, MD, PhD, Department of Neurology, Massachusetts General Hospital, 165 Cambridge Street, Office 627, Boston, MA 02114. E-mail: [email\u00a0protected]","institution_ids":["https://openalex.org/I4210087915"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5062928592"],"corresponding_institution_ids":["https://openalex.org/I4210087915"],"apc_list":null,"apc_paid":null,"fwci":0.0438,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.12290128,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"27","issue":"1","first_page":"14","last_page":"20"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T11735","display_name":"Peripheral Neuropathies and Disorders","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/neuromyelitis-optica-spectrum-disorder","display_name":"neuromyelitis optica spectrum disorder","score":1.0},{"id":"https://openalex.org/keywords/randomized-controlled-trials","display_name":"randomized controlled trials","score":0.8989999890327454},{"id":"https://openalex.org/keywords/trial-design","display_name":"trial design","score":0.6819999814033508},{"id":"https://openalex.org/keywords/seronegative-nmosd","display_name":"seronegative NMOSD","score":0.8370000123977661},{"id":"https://openalex.org/keywords/relapse","display_name":"relapse","score":0.492000013589859},{"id":"https://openalex.org/keywords/annualized-relapse-rate","display_name":"annualized relapse rate","score":0.9020000100135803},{"id":"https://openalex.org/keywords/placebo-use","display_name":"placebo use","score":0.6060000061988831},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.7609999775886536},{"id":"https://openalex.org/keywords/head-to-head-comparison","display_name":"head-to-head comparison","score":0.546999990940094},{"id":"https://openalex.org/keywords/long-term-efficacy-and-safety","display_name":"long-term efficacy and safety","score":0.7059999704360962}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9215489625930786},{"id":"https://openalex.org/C2781137167","wikidata":"https://www.wikidata.org/wiki/Q611458","display_name":"Neuromyelitis optica","level":3,"score":0.9156889915466309},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.6634358167648315},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5867497324943542},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5460827350616455},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4505902826786041},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.3713187277317047},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.3532503843307495},{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.3254598379135132},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.22099569439888},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.16394206881523132},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.13615381717681885}],"mesh":[{"descriptor_ui":"D001323","descriptor_name":"Autoantibodies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007074","descriptor_name":"Immunoglobulin G","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009471","descriptor_name":"Neuromyelitis Optica","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051401","descriptor_name":"Aquaporin 4","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/nrl.0000000000000376","doi":"https://doi.org/10.1097/nrl.0000000000000376","is_oa":false,"landing_page_url":"https://doi.org/10.1097/nrl.0000000000000376","pdf_url":null,"source":{"id":"https://openalex.org/S135892068","display_name":"The Neurologist","issn_l":"1074-7931","issn":["1074-7931","2331-2637"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Neurologist","raw_type":"journal-article"},{"id":"pmid:34855669","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/34855669","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The neurologist","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":31,"referenced_works":["https://openalex.org/W1904800945","https://openalex.org/W1975792132","https://openalex.org/W2040214350","https://openalex.org/W2046068958","https://openalex.org/W2052652578","https://openalex.org/W2053472907","https://openalex.org/W2079409038","https://openalex.org/W2100892626","https://openalex.org/W2120238028","https://openalex.org/W2129229339","https://openalex.org/W2136132690","https://openalex.org/W2140716285","https://openalex.org/W2491904945","https://openalex.org/W2524675862","https://openalex.org/W2554521349","https://openalex.org/W2747029006","https://openalex.org/W2753021216","https://openalex.org/W2782208353","https://openalex.org/W2793863481","https://openalex.org/W2943416206","https://openalex.org/W2972221943","https://openalex.org/W2991438804","https://openalex.org/W3008123935","https://openalex.org/W3012054652","https://openalex.org/W3014033701","https://openalex.org/W3018886418","https://openalex.org/W3019956952","https://openalex.org/W3026980747","https://openalex.org/W3036986101","https://openalex.org/W3047451616","https://openalex.org/W3083036202"],"related_works":["https://openalex.org/W3180748216","https://openalex.org/W3012054652","https://openalex.org/W2169081476","https://openalex.org/W4224033419","https://openalex.org/W3136438138","https://openalex.org/W4409178292","https://openalex.org/W3210877808","https://openalex.org/W3036174733","https://openalex.org/W3021112453","https://openalex.org/W3099156795"],"abstract_inverted_index":{"BACKGROUND:":[0],"Neuromyelitis":[1],"optica":[2],"spectrum":[3],"disorder":[4],"(NMOSD)":[5],"is":[6],"a":[7,77],"relapsing":[8],"inflammatory":[9],"disease":[10,201],"that":[11],"primarily":[12],"affects":[13],"the":[14,18,34,46,62,80,103,152,159,170,174,179,207,216,232],"optic":[15],"nerves":[16],"and":[17,37,49,64,102,108,125,134,154,196,237,243,245],"spinal":[19],"cord.":[20],"Randomized":[21],"controlled":[22],"trials":[23,228],"(RCTs)":[24],"assessing":[25],"treatments":[26,70],"for":[27,53,71,206,221,226],"NMOSD":[28,184,230],"have":[29],"only":[30],"been":[31],"performed":[32],"in":[33,91,149,158,166,213,229],"past":[35],"decade,":[36],"to":[38,147,182],"date,":[39],"there":[40],"are":[41],"3":[42,219],"drugs":[43],"approved":[44],"by":[45,178],"US":[47],"Food":[48],"Drug":[50],"Administration":[51],"(FDA)":[52],"antiaquaporin-4":[54],"immunoglobulin":[55,192],"G":[56,193],"seropositive":[57,222],"NMOSD.":[58,72,223],"This":[59],"review":[60,78],"assesses":[61],"characteristics":[63,198],"challenges":[65,225],"of":[66,151,187,190,209,215,218,234,240],"RCTs":[67,99,163],"when":[68],"evaluating":[69],"REVIEW":[73],"SUMMARY:":[74],"We":[75],"conducted":[76],"using":[79],"terms":[81],"(\"neuromyelitis":[82],"optica\"":[83],"OR":[84,86],"\"NMO\"":[85],"\"NMOSD\")":[87],"AND":[88],"\"clinical":[89],"trial\"":[90],"any":[92],"language":[93],"on":[94],"March":[95],"28,":[96],"2021.":[97],"Seven":[98],"were":[100,113,132,137],"included,":[101],"trials'":[104],"architecture":[105],"was":[106,145],"analyzed":[107],"synthesized.":[109],"Overall,":[110],"794":[111],"subjects":[112],"randomized":[114],"[monoclonal":[115],"antibody":[116,140],"intervention":[117],"group,":[118],"n=":[119],"493":[120],"(62.1%),":[121],"placebo,":[122],"n=196":[123],"(24.7%),":[124],"active":[126],"control,":[127],"n=105":[128],"(13.2%)];":[129],"709":[130],"(89.3%)":[131],"females;":[133],"658":[135],"(82.9%)":[136],"aquaporin-4":[138],"(AQP4)":[139],"seropositive.":[141],"The":[142],"primary":[143],"outcome":[144],"time":[146],"relapse":[148,156],"6/7":[150],"trials,":[153],"annualized":[155],"rate":[157],"remaining":[160],"one.":[161],"Four":[162],"used":[164,181],"placebo":[165,210],"their":[167],"design.":[168],"Among":[169],"seven":[171],"published":[172],"RCTs,":[173],"trial":[175,241],"design":[176,242],"differed":[177],"criteria":[180],"define":[183],"relapse,":[185],"selection":[186],"subjects,":[188],"proportion":[189],"AQP4":[191],"seronegative":[194],"patients,":[195],"baseline":[197],"indicating":[199],"NMO":[200],"severity.":[202],"CONCLUSIONS:":[203],"Ethical":[204],"considerations":[205],"use":[208],"should":[211],"change":[212],"light":[214],"approval":[217],"therapies":[220],"Remaining":[224],"clinical":[227],"include":[231],"assessment":[233],"long-term":[235],"safety":[236],"efficacy,":[238],"standardization":[239],"endpoints,":[244],"head-to-head":[246],"study":[247],"designs.":[248]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2021-12-06T00:00:00"}